Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial

H Chih-Ho Hong; David N Adam; Jason K Rivers; Marni C Wiseman; Henrik Thoning; Clinton B McCracken

doi:10.1177/12034754221139265

Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial

J Cutan Med Surg. 2023 Jan-Feb;27(1):63-64. doi: 10.1177/12034754221139265. Epub 2022 Nov 28.

Authors

H Chih-Ho Hong^{1

2}, David N Adam^{2

3

4}, Jason K Rivers^{1

2

5}, Marni C Wiseman^{6

7}, Henrik Thoning⁸, Clinton B McCracken⁹

Affiliations

¹ 8166 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
² Probity Medical Research, Waterloo, ON, Canada.
³ 7938 Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, ON, Canada.
⁴ CCA Medical Research, Ajax, ON, Canada.
⁵ Pacific Derm, Vancouver, Vancouver, BC Canada.
⁶ 12359 Section of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.
⁷ Skinwise Dermatology, Winnipeg, MB, Canada.
⁸ LEO Pharma A/S, Ballerup, Denmark.
⁹ 1460 LEO Pharma Canada, Thornhill, ON, Canada.

PMID: 36437761
DOI: 10.1177/12034754221139265

No abstract available

Keywords: Canadian subgroup analysis; calcipotriol/betamethasone dipropionate foam; long-term efficacy; maintenance therapy; plaque psoriasis; proactive therapy; safety.

Publication types

Clinical Trial, Phase III
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Topical
Betamethasone / therapeutic use
Canada
Dermatologic Agents* / therapeutic use
Drug Combinations
Humans
Psoriasis* / drug therapy
Treatment Outcome

Substances

Betamethasone
Dermatologic Agents
Drug Combinations